Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.
J Allergy Clin Immunol Pract
; 7(6): 1894-1900, 2019.
Article
em En
| MEDLINE
| ID: mdl-30776524
ABSTRACT
BACKGROUND:
Hypersensitivity reactions to platinum salts (PS) (cisplatin [CI], carboplatin [CA], and oxaliplatin [OX]) can be severe and their incidence is increasing due to their widespread use in cancer treatment.OBJECTIVE:
To determine the rate of cross-reactivity between PS and whether CI can be administered without prior allergy testing in patients with a history of CA or OX hypersensitivity.METHODS:
From September 2002 to April 2016, patients with suspected immediate PS hypersensitivity were tested and cross-reactivity between the 3 PS was evaluated. We then studied patients who were given CI without desensitization after immediate hypersensitivity to other PS.RESULTS:
A total of 155 patients were included. Skin tests were positive in 97 patients (OX 51, CA 43, and CI 3). Cross-reactivity to CA in OX-allergic patients was 45% (23 of 51) (95% confidence interval [CI] 36% to 66%) and cross-reactivity to OX in CA-allergic patients was 37% (16 of 43) (95% CI 23% to 53%). In contrast, cross-reactivity to CI was 0% (0 of 51) (95% CI 0% to 7%) in OX-allergic patients and 7% (3 of 43) (95% CI 2% to 17%) in CA-allergic patients. All these 3 patients had previously been exposed to CI in previous courses of chemotherapy. CI was initiated in 24 patients with proven hypersensitivity to CA or OX and had no hypersensitivity reactions.CONCLUSION:
Initiating CI in patients with proven immediate hypersensitivity to CA or OX appeared to be safe in our study.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carboplatina
/
Compostos de Platina
/
Hipersensibilidade a Drogas
/
Oxaliplatina
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article